Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

ECC0509 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our USA and Australia registers that name ECC0509 as an intervention. Synced 15 Oct 2026
2Current trials
1Recruiting now
1Lead sponsor
2Country registers
At a glance

ECC0509 is named as an intervention in 2 current clinical trials in our USA and Australia registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Eccogene. The most-studied condition is Metabolic Dysfunction-associated Steatohepatitis.

Patient leaflets for ECC0509

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting150%
  • Not yet open150%

Trials by phase

  • Phase 2150%
  • Phase 1150%
01

Clinical trials of ECC0509

2 trials
StudyPhaseStatusLead sponsorRegisters
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138 · Metabolic Dysfunction-associated Steatohepatitis
Phase 2 Recruiting Eccogene USA
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
NCT07873229 · ClinicalTrials.gov ↗ · Steatohepatitis, Nonalcoholic, Osteo Arthritis
Phase 1 Not yet open Eccogene Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with ECC0509

3 conditions
Metabolic Dysfunction-associated Steatohepatitis1Steatohepatitis, Nonalcoholic1Osteo Arthritis1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Eccogene2
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA11
Clinical trials in Australia10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about ECC0509 trials

How many clinical trials are testing ECC0509?

2 current trials in our USA and Australia registers name ECC0509 as a drug or biological intervention, as of the registry sync on 15 October 2026. Completed and withdrawn studies are not counted.

Are ECC0509 trials recruiting patients?

Yes. 1 of the 2 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors ECC0509 clinical trials?

The lead sponsor is Eccogene. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ECC0509 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ECC0509 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ECC0509 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 15 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.